// App-Quantinova.ai

6028 : Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

Researchers

Presenter

  • Irene Brana

Principal Investigators

  • Martin Forster

  • Antonio Lopez-Pousa

  • Bernard Doger

  • Patricia Roxburgh

  • Pawan Bajaj

  • Daniela Urueta Portillo

  • Vanesa Quiroga

  • Matthew Krebs

  • Christian Mueller

  • Frederic Triebel

Medical Centers

  • Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Barcelona, Spain

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Hospital De Sant Pau, Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Institute of Cancer Sciences, University of Glasgow and The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Tasman Oncology Research, Queensland, Australia

  • Oncology Consultants PA, Houston, TX

  • Badalona-Applied Research Group in Oncology: B-ARGO Group, Catalan Institute of Oncology, Spain-GEICAM, Spanish Breast Cancer Group, Barcelona, Spain

  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

  • Clinical Development, Immutep, Berlin, Germany

  • Research & Development, Immutep, Paris, France

Locations

  • Spain

  • United Kingdom

  • Australia

  • Germany

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • EDP 202

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • II

Study Id's

  • NCT03625323

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved